<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "1: NUTRITION ", fill: "#de6fa1"},
{source: "1: NUTRITION ", target: "1: investment", fill: "#de6fa1"},
{source: "1: investment", target: "1: following risks among others", fill: "#de6fa1"},
{source: "1: NUTRITION ", target: "5: accretion", fill: "#004b49"},
{source: "5: accretion", target: "5: debt discount", fill: "#004b49"},
{source: "5: debt discount", target: "5: amortization", fill: "#004b49"},
{source: "5: amortization", target: "5: debt issuance", fill: "#004b49"},
{source: "5: debt issuance", target: "5: costs on preferred stock", fill: "#004b49"},
{source: "5: accretion", target: "6: additional", fill: "#8a496b"},
{source: "6: additional", target: "6: securities may increase", fill: "#8a496b"},
{source: "6: additional", target: "7: will likely continue", fill: "#91a3b0"},
{source: "7: will likely continue", target: "7: future should", fill: "#91a3b0"},
{source: "7: future should", target: "7: significantly", fill: "#91a3b0"},
{source: "7: significantly", target: "7: retail distribution", fill: "#91a3b0"},
{source: "7: retail distribution", target: "7: arrangements reached with mass retailers", fill: "#91a3b0"},
{source: "7: will likely continue", target: "12: Iceland Health in August ", fill: "#e3ff00"},
{source: "12: Iceland Health in August ", target: "12: financial statements", fill: "#e3ff00"},
{source: "12: financial statements", target: "12: acquisition until", fill: "#e3ff00"},
{source: "12: acquisition until", target: "12: as permitted by relevant", fill: "#e3ff00"},
{source: "12: as permitted by relevant", target: "12: regulations", fill: "#e3ff00"},
{source: "12: Iceland Health in August ", target: "14: significant", fill: "#800080"},
{source: "14: significant", target: "14: contributions", fill: "#800080"},
{source: "14: contributions", target: "14: Iceland Health ", fill: "#800080"},
{source: "14: Iceland Health ", target: "14: Companys ", fill: "#800080"},
{source: "14: Companys ", target: "14: depends among", fill: "#800080"},
{source: "14: depends among", target: "14: Companys ", fill: "#800080"},
{source: "14: Companys ", target: "14: Iceland Healths ", fill: "#800080"},
{source: "14: Iceland Healths ", target: "14: distribution channels with strong marketing campaigns", fill: "#800080"},
{source: "14: distribution channels with strong marketing campaigns", target: "14: integration", fill: "#800080"},
{source: "14: significant", target: "20: Northern Arizona University ", fill: "#696969"},
{source: "20: Northern Arizona University ", target: "20: administered chromium picolinate", fill: "#696969"},
{source: "20: administered chromium picolinate", target: "20: laboratory", fill: "#696969"},
{source: "20: laboratory", target: "20: hamster ovary", fill: "#696969"},
{source: "20: hamster ovary", target: "20: cell lines", fill: "#696969"},
{source: "20: cell lines", target: "20: safety concerns", fill: "#696969"},
{source: "20: Northern Arizona University ", target: "27: product liability insurance", fill: "#0070ff"},
{source: "27: product liability insurance", target: "40: markets chromium polynicotinate", fill: "#000f89"},
{source: "40: markets chromium polynicotinate", target: "44: depend on", fill: "#228b22"},
{source: "44: depend on", target: "44: scientific consensus", fill: "#228b22"},
{source: "44: scientific consensus", target: "44: supplement offers", fill: "#228b22"},
{source: "44: supplement offers", target: "44: competitive with", fill: "#228b22"},
{source: "44: competitive with", target: "44: numerous products offered by", fill: "#228b22"},
{source: "44: numerous products offered by", target: "44: participate", fill: "#228b22"},
{source: "44: depend on", target: "48: competitors", fill: "#000080"},
{source: "48: competitors", target: "48: major companies with", fill: "#000080"},
{source: "48: major companies with", target: "48: product divisions", fill: "#000080"},
{source: "48: product divisions", target: "48: development", fill: "#000080"},
{source: "48: development", target: "48: dietary supplements", fill: "#000080"},
{source: "48: competitors", target: "77: The FTC ", fill: "#007fbf"},
{source: "77: The FTC ", target: "77: advertising", fill: "#007fbf"},
{source: "77: advertising", target: "77: difficult", fill: "#007fbf"},
{source: "77: The FTC ", target: "80: significant patents consist", fill: "#adff2f"},
{source: "80: significant patents consist", target: "80: three method", fill: "#adff2f"},
{source: "80: three method", target: "80: chromium picolinate", fill: "#adff2f"},
{source: "80: chromium picolinate", target: "80: composition glucose stabilization", fill: "#adff2f"},
{source: "80: composition glucose stabilization", target: "80: composition", fill: "#adff2f"},
{source: "80: composition", target: "80: cholesterol maintenance", fill: "#adff2f"},
{source: "80: cholesterol maintenance", target: "80: four patents", fill: "#adff2f"},
{source: "80: four patents", target: "80: depression", fill: "#adff2f"},
{source: "80: depression", target: "80: premenstrual syndrome", fill: "#adff2f"},
{source: "80: premenstrual syndrome", target: "80: two composition", fill: "#adff2f"},
{source: "80: two composition", target: "80: cover chromium", fill: "#adff2f"},
{source: "80: cover chromium", target: "80: biotin compositions", fill: "#adff2f"},
{source: "80: biotin compositions", target: "80: compositions", fill: "#adff2f"},
{source: "80: compositions", target: "80: stabilizing serum", fill: "#adff2f"},
{source: "80: stabilizing serum", target: "80: one composition", fill: "#adff2f"},
{source: "80: one composition", target: "80: ingredients", fill: "#adff2f"},
{source: "80: ingredients", target: "80: offer products", fill: "#adff2f"},
{source: "80: significant patents consist", target: "82: patent protection", fill: "#b57281"},
{source: "82: patent protection", target: "82: market products", fill: "#b57281"},
{source: "82: market products", target: "82: adversely affected since", fill: "#b57281"},
{source: "82: adversely affected since", target: "82: competition on", fill: "#b57281"},
{source: "82: patent protection", target: "100: period during which", fill: "#796878"},
{source: "100: period during which", target: "100: common stock will continue", fill: "#796878"},
{source: "100: common stock will continue", target: "100: Nasdaq Capital Market ", fill: "#796878"},
{source: "100: Nasdaq Capital Market ", target: "100: extended further", fill: "#796878"},
{source: "100: extended further", target: "100: certain conditions", fill: "#796878"},
{source: "100: period during which", target: "102: Should the Company ", fill: "#228b22"},
{source: "102: Should the Company ", target: "102: compliance at", fill: "#228b22"},
{source: "102: compliance at", target: "102: common stock will", fill: "#228b22"},
{source: "102: common stock will", target: "102: delisting from", fill: "#228b22"},
{source: "102: Should the Company ", target: "START_HERE", fill: "#228b22"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Advertising</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Trading Companies and Distributors</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Vote</td>
    </tr>
    <tr>
      <td>Host meeting</td>
    </tr>
    <tr>
      <td>Empathize</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Human death</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Reduce routine activity</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Yield position</td>
    </tr>
    <tr>
      <td>Reward</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Nutrition">Nutrition</a></td>
      <td>Nutrition is the biochemical and physiological process by which an organism uses food to support its life.  It includes ingestion, absorption, assimilation, biosynthesis, catabolism and excretion.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Herbalife_Nutrition">Herbalife Nutrition</a></td>
      <td>Herbalife Nutrition Ltd. is a global multi-level marketing (MLM) corporation that develops and sells dietary supplements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Malnutrition">Malnutrition</a></td>
      <td>Malnutrition occurs when an individual gets too few or too many nutrients, resulting in health problems. Specifically, it is "a deficiency, excess, or imbalance of energy, protein and other nutrients" which adversely affects the body's tissues and form.Malnutrition is a category of diseases that includes undernutrition and overnutrition.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Human_nutrition">Human nutrition</a></td>
      <td>Human nutrition deals with the provision of essential nutrients in food that are necessary to support human life and good health. Poor nutrition is a chronic problem often linked to poverty, food security, or a poor understanding of nutritional requirements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Holozoic_nutrition">Holozoic nutrition</a></td>
      <td>Holozoic nutrition (Greek: holo-whole ; zoikos-of animals) is a type of heterotrophic nutrition that is characterized by the internalization (ingestion) and internal processing of liquids or solid food particles.  Protozoa, such as amoebas, and most of the free living animals, such as humans, exhibit this type of nutrition where food is taken into the body as a liquid or solid and then further broken down is called as holozoic nutrition.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Nutritional_science">Nutritional science</a></td>
      <td>Nutritional science (also nutrition science, sometimes short nutrition, dated trophology) is the science that studies the physiological process of nutrition (primarily human nutrition), interpreting the nutrients and other substances in food in relation to maintenance, growth, reproduction, health and disease of an organism.\n\n\n== History ==\nBefore nutritional science emerged as an independent study disciplines, mainly chemists worked in this area.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Stock_market">Stock market</a></td>
      <td>A stock market, equity market, or share market is the aggregation of buyers and sellers of stocks (also called shares), which represent ownership claims on businesses; these may include securities listed on a public stock exchange, as well as stock that is only traded privately, such as shares of private companies which are sold to investors through equity crowdfunding platforms. Investment is usually made with an investment strategy in mind.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Securities_fraud">Securities fraud</a></td>
      <td>Securities fraud, also known as stock fraud and investment fraud, is a deceptive practice in the stock or commodities markets that induces investors to make purchase or sale decisions on the basis of false information, frequently resulting in losses, in violation of securities laws.Securities fraud can also include outright theft from investors (embezzlement by stockbrokers), stock manipulation, misstatements on a public company's financial reports, and lying to corporate auditors. The term encompasses a wide range of other actions, including insider trading, front running and other illegal acts on the trading floor of a stock or commodity exchange.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Internet">Internet</a></td>
      <td>In finance and economics, interest is payment from a borrower or deposit-taking financial institution to a lender or depositor of an amount above repayment of the principal sum (that is, the amount borrowed), at a particular rate. It is distinct from a fee which the borrower may pay the lender or some third party.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Holding_company">Holding company</a></td>
      <td>A holding company is a company whose primary business is holding a controlling interest in the securities of other companies. A holding company usually does not produce goods or services itself.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Chromium(III)_picolinate">Chromium(III) picolinate</a></td>
      <td>Chromium(III) picolinate is a chemical compound with the formula Cr(C5H4N(CO2H))3, commonly abbreviated as CrPic3. It is sold as a nutritional supplement to treat type 2 diabetes and promote weight loss.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Chromium_in_glucose_metabolism">Chromium in glucose metabolism</a></td>
      <td>Chromium is claimed to be an essential element involved in the regulation of blood glucose levels within the body. More recent reviews have questioned this, however.It is believed to interact with the low-molecular weight chromium (LMWCr) binding substance to amplify the action of insulin.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/In-car_entertainment">In-car entertainment</a></td>
      <td>In-car entertainment (ICE), or in-vehicle infotainment (IVI), is a collection of hardware and software in automobiles that provides audio or video entertainment. In car entertainment originated with car audio systems that consisted of radios and cassette or CD players, and now includes automotive navigation systems, video players, USB and Bluetooth connectivity, Carputers, in-car internet, and WiFi.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Data_monitoring_committee">Data monitoring committee</a></td>
      <td>A data monitoring committee (DMC) – sometimes called a data and safety monitoring board (DSMB) – is an independent group of experts who monitor patient safety and treatment efficacy data while a clinical trial is ongoing.\n\n\n== Need for a DMC ==\nMany randomized clinical trials are double blind – no one involved with the trial knows what treatment is to be given to each trial participant.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Shein_(company)">Shein (company)</a></td>
      <td>Shein ( SHEE-in; styled as SHEIN; Chinese: 希音; pinyin: Xīyīn) is a Chinese online fast fashion retailer. It was founded in 2008 by Chris Xu in Nanjing, China.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Whiteman_Airport">Whiteman Airport</a></td>
      <td>Whiteman Airport (previously known as Whiteman Air Park) (IATA: WHP, ICAO: KWHP) is a general aviation airport in the northeastern San Fernando Valley community of Pacoima, in the city of Los Angeles, California, United States.\nThe airport was founded as Whiteman Air Park in 1946 on a farm by pilot Marvin Whiteman Sr.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Maggi">Maggi</a></td>
      <td>Maggie is a common short form of the name Margaret, Magda, Magdalena, Margarida and Magnolia.\nMaggie may refer to:\n\n\n== People ==\n\n\n=== Women ===\nMaggie Adamson, Scottish musician\nMaggie Aderin-Pocock (born 1968), British scientist\nMaggie Alderson (born 1959), Australian author\nMaggie Alphonsi (born 1983), English rugby union player\nMaggie Anderson (born 1948), American poet\nMaggie Anderson (activist) (born 1971), American activist\nMaggie Atkinson (born 1956), English educator\nMaggie Ausburn (born 1978), American TV actor\nMaggie Baird (born 1959), American actress\nMaggie Bandur (born 1974), American television writer\nMaggie Barrie (born 1996), Sierra Leonean sprinter\nMaggie Barry (born 1959), New Zealand politician\nMaggie Batson (born 2003), American actress\nMaggie Baylis (1912–1997), American graphic designer\nMaggie Beer (born 1945), Australian cook\nMaggie Behle (born 1980), American Paralympic alpine skier\nMaggie Bell (born 1945), Scottish vocalist\nMaggie Benedict (born 1981), South African actress\nMaggie Betts, American filmmaker\nMaggie Björklund, Danish guitarist\nMaggie Black (1930–2015), American ballet teacher\nMaggie Blanc, American television producer\nMaggie De Block (born 1962), Belgian politician\nMaggie Blye (1942–2016), American actress\nMaggie Borg (1952–2004), Maltese activist\nMaggie Boyle (1956–2014), English singer\nMaggie Bridges (born 1992), American beauty pageant titleholder\nMaggie Brown (born 1948), American playwright\nMaggie Brown (singer) (born 1963), American singer\nMaggie Browne (1864–1937), English author\nMaggie Butt, British poet\nMaggie Calloway (born 1910), Filipino actress\nMaggie Campbell-Culver, English historian\nMaggie Carey (born 1975), American director\nMaggie Carlton (born 1957), American politician\nMaggie Carver (born 1964), English businesswoman\nMaggie Cassella, American-Canadian actress\nMaggie Chan (born 1975), Hong Kong long-distance runner\nMaggie Chapman (born 1979), Zimbabwean-Scottish politician\nMaggie Chapman (singer) (born 1997), American singer-songwriter\nMaggie Chen (born 1957), Chinese actress\nMaggie Cheung (born 1964), Hong Kong actress\nMaggie Cheung Ho-yee (born 1969), Hong Kong actress\nMaggie Chiang (born 1980), Taiwanese singer\nMaggie Civantos (born 1984), Spanish actress\nMaggie Cline (1857–1934), American singer\nMaggie Cogan (born 1943), American resident\nMaggie Coles-Lyster (born 1999), Canadian cyclist\nMaggie Collins, Australian announcer\nMaggie Cronin, Irish actress\nMaggie Crotty (born 1948), Democratic member\nMaggie Cusack, English professor\nMaggie Eckford (born c.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Safety">Safety</a></td>
      <td>Safety is the state of being "safe", the condition of being protected from harm or other danger. Safety can also refer to the control of recognized hazards in order to achieve an acceptable level of risk.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Legal_liability">Legal liability</a></td>
      <td>In law, liable means  "responsible or answerable in law; legally obligated". Legal liability concerns both civil law and criminal law and can arise from various areas of law, such as contracts, torts, taxes, or fines given by government agencies.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Competition">Competition</a></td>
      <td>Competition is a rivalry where two or more parties strive for a common goal which cannot be shared: where one's gain is the other's loss (an example of which is a zero-sum game). Competition can arise between entities such as organisms, individuals, economic and social groups, etc.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Sport_of_athletics">Sport of athletics</a></td>
      <td>Athletics is a group of sporting events that involves competitive running, jumping, throwing, and walking. The most common types of athletics competitions are track and field, road running, cross country running, and racewalking.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Dietary_Supplement_Health_and_Education_Act_of_1994">Dietary Supplement Health and Education Act of 1994</a></td>
      <td>The Dietary Supplement Health and Education Act of 1994 ("DSHEA"), is a 1994 statute of United States Federal legislation which defines and regulates dietary supplements. Under the act, supplements are effectively regulated by the FDA for Good Manufacturing Practices under 21 CFR Part 111.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Difficult_Loves">Difficult Loves</a></td>
      <td>Difficult Loves (Italian: Gli amori difficili) is a 1970 short story collection by Italo Calvino. It concerns love and the difficulty of communication.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/A_Difficult_Woman">A Difficult Woman</a></td>
      <td>A Difficult Woman is an Australian television series which screened in 1998 on the ABC. The three part series starred Caroline Goodall, in the title role of a woman whose best friend is murdered and is determined to find out why. It was written by Nicholas Hammond and Steven Vidler and directed by Tony Tilse.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/For_Love_or_Money_(2014_film)">For Love or Money (2014 film)</a></td>
      <td>For Love or Money (Chinese: 露水红颜) is a Chinese romance film based on Hong Kong novelist Amy Cheung's 2006 novel of the same name. The film was directed by Gao Xixi and starring Liu Yifei and Rain.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Difficult_Couple">The Difficult Couple</a></td>
      <td>The Difficult Couple (Chinese: 难夫难妻; pinyin: Nànfū Nànqī), also translated as Die for Marriage, is a 1913 Chinese film. It is known for being the earliest Chinese feature film.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/The_Globe_Sessions">The Globe Sessions</a></td>
      <td>The Globe Sessions is the third studio album by American singer-songwriter Sheryl Crow, released on September 21, 1998, in the United Kingdom and September 29, 1998, in the United States, then re-released in 1999. It was nominated for Album of the Year, Best Rock Album and Best Engineered Non-Classical Album at the 1999 Grammys, winning the latter two awards.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Musical_composition">Musical composition</a></td>
      <td>Musical composition can refer to an original piece or work of music, either vocal or instrumental, the structure of a musical piece or to the process of creating or writing a new piece of music. People who create new compositions are called composers.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Composition_VII">Composition VII</a></td>
      <td>Composition VII is an abstract oil painting executed in 1913 by Wassily Kandinsky, a Russian-born painter. It is in the collection of the Tretyakov Gallery, Moscow.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Function_composition">Function composition</a></td>
      <td>In mathematics, function composition is an operation  ∘  that takes two functions f and g, and produces a function h = g  ∘  f such that h(x) = g(f(x)). In this operation, the function g is applied to the result of applying the function f to x.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Composition_of_the_German_state_parliaments">Composition of the German state parliaments</a></td>
      <td>Germany's federal system comprises 16 state parliaments (the German terms are: Landtag in large states, Bürgerschaft in Bremen and Hamburg, Abgeordnetenhaus in Berlin), each including directly elected representatives.\n\n\n== Parties in each parliament ==\n\nIn the table below, the parties with shading form part of the state government whilst the parties in bold are the largest party in that legislature.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Patent_troll">Patent troll</a></td>
      <td>In international law and business, patent trolling or patent hoarding is a categorical or pejorative term applied to a person or company that attempts to enforce patent rights against accused infringers far beyond the patent's actual value or contribution to the prior art, often through hardball legal tactics (frivolous litigation, vexatious litigation, strategic lawsuits against public participation (SLAPP), chilling effects, and the like). Patent trolls often do not manufacture products or supply services based upon the patents in question.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Patent">Patent</a></td>
      <td>A patient is any recipient of health care services that are performed by healthcare professionals. The patient is most often ill or injured and in need of treatment by a physician, nurse, optometrist, dentist, veterinarian, or other health care provider.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock">Common stock</a></td>
      <td>Common stock is a form of corporate equity ownership, a type of security. The terms voting share and ordinary share are also used frequently outside of the United States.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><font color="blue">NUTRITION </font>21 INC      Item 1A RISK FACTORS       An <font color="blue">investment</font> in the Company involves the following risks, among others</td>
    </tr>
    <tr>
      <td>WE HAVE NOT BEEN PROFITABLE FOR THE LAST FOUR FISCAL YEARS       We had net losses of dlra10dtta317 million, dlra7dtta044 million, dlra5dtta901 million and     dlra10dtta506 million for the <font color="blue">fiscal years</font> ended on June 30, 2006, 2005, 2004, and     2003, respectively</td>
    </tr>
    <tr>
      <td>We have had net operating <font color="blue">losses periodically from</font> our     <font color="blue">inception as</font> a Company in 1983 through the fiscal year ended June 30, 2006</td>
    </tr>
    <tr>
      <td><font color="blue">As of June </font>30, 2006, our accumulated losses aggregated <font color="blue">approximately</font> dlra72dtta285     million</td>
    </tr>
    <tr>
      <td>In the <font color="blue">fiscal years</font> ending June 30, 2007, 2008 and 2009, respectively, we     expect to incur <font color="blue">approximately</font> dlra1dtta0 million, dlra1dtta0 million and dlra0dtta8 million of     expenses for <font color="blue">accretion</font> of <font color="blue">debt discount</font> and <font color="blue">amortization</font> of <font color="blue">debt issuance</font>     <font color="blue">costs on preferred stock</font> we issued in 2005</td>
    </tr>
    <tr>
      <td>The issuance of <font color="blue">additional</font>     <font color="blue">securities may increase</font> these expenses</td>
    </tr>
    <tr>
      <td>RISK ASSOCIATED WITH MARKETING       We <font color="blue">will likely continue</font> to be unprofitable in the <font color="blue">future should</font> we fail to     increase  our  revenues  <font color="blue"><font color="blue">significant</font>ly</font>  from  the  <font color="blue">retail distribution</font>     <font color="blue"><font color="blue">arrangements</font> reached with mass retailers</font></td>
    </tr>
    <tr>
      <td>To succeed with these <font color="blue">arrangements</font>     we  will have to launch and maintain <font color="blue">successful marketing campaigns</font> to     <font color="blue">encourage consumers</font> to <font color="blue">purchase <font color="blue">branded products</font> stocked by</font> these retailers</td>
    </tr>
    <tr>
      <td>Our failure to <font color="blue">promptly stimulate such demand could</font> cause retailers to     terminate their <font color="blue"><font color="blue">relationship</font> with us</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">arrangements</font> with mass retailers     are <font color="blue">terminable by them on</font> notice</td>
    </tr>
    <tr>
      <td>During the fourth quarter of fiscal year     2006,  the  revenue  recognized  from  shipments to mass retailers was     <font color="blue">approximately</font> dlra0dtta2 million</td>
    </tr>
    <tr>
      <td>RISK ASSOCIATED WITH THE ACQUISITION OF ICELAND HEALTH, INC       We acquired <font color="blue"><font color="blue">Iceland Health </font>in August </font>2006 and do not expect to file with the     SEC <font color="blue">financial statements</font> related to the <font color="blue"><font color="blue">acquisition</font> until</font> November 8, 2006,     <font color="blue">as permitted by relevant</font> SEC <font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Accordingly </font>investors do not now     have information about this <font color="blue">acquisition</font> that <font color="blue">would likely</font> be useful to them     in their <font color="blue">assessment</font> of the business prospects of Iceland Health’s business</td>
    </tr>
    <tr>
      <td>In any event, <font color="blue">significant</font> positive <font color="blue">contributions</font> by <font color="blue">Iceland Health </font>on the     Company’s results depends, among other things, on the Company’s ability to     successfully introduce Iceland Health’s omega-3 products into the Companyapstas     <font color="blue">distribution channels with strong marketing campaigns</font>, and on the successful     <font color="blue">integration</font> of <font color="blue">Iceland Health </font>into our current business</td>
    </tr>
    <tr>
      <td>23       _________________________________________________________________         POSSIBLE NEED FOR ADDITIONAL FUNDS       To support the marketing and other expenses we envision, we may also need to     raise <font color="blue">additional</font> funds</td>
    </tr>
    <tr>
      <td>There is no assurance that <font color="blue">additional</font> funds will be     <font color="blue">available on terms</font> favorable to the Company and its <font color="blue">shareholders</font>, or at all</td>
    </tr>
    <tr>
      <td>RISK ASSOCIATED WITH LACK OF DIVERSIFICATION       Our business currently depends on two basic products: <font color="blue">chromium picolinate</font>     and related compounds, and omega 3 fish oils and <font color="blue">fatty acids</font></td>
    </tr>
    <tr>
      <td>Our failure to     <font color="blue">diversify beyond</font> these products could affect us adversely if, for whatever     reason, we do not achieve satisfactory levels of sales of these products</td>
    </tr>
    <tr>
      <td>SEVERAL RESEARCHERS HAVE QUESTIONED THE SAFETY OF CHROMIUM PICOLINATE, AND     WE MAY BE LIABLE FOR DAMAGES IF OUR PRODUCTS ARE PROVEN TO HAVE HARMFUL SIDE     EFFECTS       In  1995  and  2002,  a research group <font color="blue">headed by</font> Dianne Stearns, Ph</td>
    </tr>
    <tr>
      <td>D     (University  of  Dartmouth  College  and  Northern Arizona University)     <font color="blue"><font color="blue">administered chromium</font> picolinate</font> in a <font color="blue">laboratory</font> to Chinese <font color="blue">hamster ovary</font>     <font color="blue">cell lines</font> and reported <font color="blue">safety concerns</font></td>
    </tr>
    <tr>
      <td>Also, in 2003, a research group     <font color="blue">headed by</font> John Vincent, Ph</td>
    </tr>
    <tr>
      <td>D (University of Alabama) <font color="blue">administered chromium</font>     picolinate to <font color="blue">fruit flies</font> and reported <font color="blue">safety concerns</font></td>
    </tr>
    <tr>
      <td>See “The Chromium Franchise” for recent safety <font color="blue">announcements</font> issued by the     United States’ Food &amp; Drug Administration (FDA) and the United Kingdom’s     Food Standards Agency (FSA)</td>
    </tr>
    <tr>
      <td>However, the Stearns and Vincent studies can     <font color="blue">nevertheless reduce</font> the <font color="blue">marketability</font> of our products</td>
    </tr>
    <tr>
      <td>In addition, if in     fact <font color="blue">safety concerns</font> are well founded for humans, our <font color="blue">viability will</font> be     <font color="blue">affected since</font> our revenues are <font color="blue">primarily derived from</font> the sale of chromium     picolinate for inclusion in <font color="blue">nutritional supplement products</font></td>
    </tr>
    <tr>
      <td>Harmful <font color="blue">effects could also</font> result in <font color="blue">legal action against</font> our Company</td>
    </tr>
    <tr>
      <td>We     have  dlra5dtta0  million of <font color="blue">product <font color="blue">liability</font> insurance</font> for the products we     currently  market and intend to obtain <font color="blue">product <font color="blue">liability</font> insurance</font> for     products we will market in the future</td>
    </tr>
    <tr>
      <td>We may not succeed in obtaining     <font color="blue">additional</font> insurance or obtaining <font color="blue">insurance sufficient</font> to cover all possible     <font color="blue">liabilities</font></td>
    </tr>
    <tr>
      <td>No material <font color="blue">liability</font> claims have been asserted <font color="blue">against us</font> to     date</td>
    </tr>
    <tr>
      <td>WE HAVE LIMITED EXPERIENCE IN SALES TO THE CONSUMER MARKET       We have limited experience in sales of <font color="blue">branded products</font> to the consumer     market, and we have not <font color="blue">been successful</font> in this market</td>
    </tr>
    <tr>
      <td>Although we have     entered into distribution <font color="blue">arrangements</font> with mass retailers, we have only     limited experience in marketing to the <font color="blue">consumer market</font></td>
    </tr>
    <tr>
      <td>We have hired the     former  principals of <font color="blue">Iceland Health </font><font color="blue">as <font color="blue">executives</font></font> of the Company but,     although these <font color="blue">executives</font> have experience in <font color="blue">direct response marketing</font>, they     have not engaged in <font color="blue">distribution through retail channels</font></td>
    </tr>
    <tr>
      <td>TO SELL PRODUCTS IN HEALTH CARE CHANNELS, WE WILL HAVE TO SUCCESSFULLY     COMMUNICATE OUR PRODUCT HEALTH BENEFITS TO THE MEDICAL COMMUNITY       We plan to <font color="blue">build awareness</font> for our <font color="blue">products through media campaigns</font> that     leverage  <font color="blue">research outcomes</font>, and <font color="blue">through testimonials from health care</font>     <font color="blue">professionals</font></td>
    </tr>
    <tr>
      <td>If these efforts are not successful we will not be able to     compete in this market and the products we propose for this <font color="blue">market will</font>     fail</td>
    </tr>
    <tr>
      <td>24       _________________________________________________________________             IF WE ARE UNABLE TO DEFEND OUR MARKET POSITION FROM LARGER, BETTER-FINANCED     COMPETITORS, OUR BUSINESS COULD SUFFER       In considering our <font color="blue">competitive position</font> in chromium-based products, we     distinguish between our <font color="blue">existing <font color="blue">ingredients</font></font> business, on the one hand, and     our  prospective therapeutic <font color="blue">branded products</font>, on the other</td>
    </tr>
    <tr>
      <td>We have a     <font color="blue">relatively strong position</font> for existing stand-alone chromium sales where we     believe that we have an <font color="blue">approximately</font> 80prca share of the market, and we have a     15prca market share for sales of chromium into multi-ingredient products, based     on reports <font color="blue">on retail sales furnished by</font> <font color="blue">SPINS and Information Resources Inc</font></td>
    </tr>
    <tr>
      <td><font color="blue">SPINS and Information Resources Inc</font></td>
    </tr>
    <tr>
      <td>are in the business of <font color="blue">providing sales</font>     and <font color="blue">marketing data</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">major competitor</font> is <font color="blue"><font color="blue">InterHealth </font>Nutraceuticals Inc</font></td>
    </tr>
    <tr>
      <td>which is a privately held company that <font color="blue">markets chromium polynicotinate</font></td>
    </tr>
    <tr>
      <td>Based on SPINS data, we estimate that <font color="blue">InterHealth </font>has <font color="blue">approximately</font> a 12prca     share of the market for stand-alone chromium sales</td>
    </tr>
    <tr>
      <td>Our therapeutic branded business <font color="blue">confronts</font> many large <font color="blue">established companies</font>     in a huge industry that serves the <font color="blue">diabetes therapeutic market</font></td>
    </tr>
    <tr>
      <td>The market     is served by the <font color="blue">major pharmaceutical companies such as</font> Eli Lilly, Johnson &amp;     Johnson,  Bristol-Myers Squibb, and GlaxoSmithKline that <font color="blue">offer various</font>     <font color="blue">medications</font> to <font color="blue">diabetics</font></td>
    </tr>
    <tr>
      <td>Our success in this arena will in large part     <font color="blue">depend on</font> our obtaining a <font color="blue">scientific consensus</font> that our <font color="blue">supplement offers</font>     benefits  that  are  <font color="blue">competitive with</font> the <font color="blue">numerous products offered by</font>     companies that <font color="blue">participate</font> in this business</td>
    </tr>
    <tr>
      <td>Our omega-3 business is <font color="blue">highly competitive</font></td>
    </tr>
    <tr>
      <td>As we enter <font color="blue">retail distribution</font>     channels  with  our omega-3 products, we will be entering an intensely     <font color="blue">competitive market with</font> large <font color="blue">established companies</font> and <font color="blue">brands such as</font>     Bumble Bee Seafoods, Nordic Naturals and Puritan’s Pride</td>
    </tr>
    <tr>
      <td>The <font color="blue">nutritional product industry</font> and the related <font color="blue">drug industries</font> are, of     course, intensely competitive</td>
    </tr>
    <tr>
      <td>Our <font color="blue">competitors</font> include <font color="blue">major companies with</font>     raw  materials  and finished <font color="blue">product divisions</font> that also engage in the     <font color="blue">development</font> and sale of <font color="blue">dietary supplements</font></td>
    </tr>
    <tr>
      <td>The great majority of these     <font color="blue">competitors</font> have financial and <font color="blue">technical resources as well as production</font> and     marketing capabilities substantially greater than ours</td>
    </tr>
    <tr>
      <td>In addition, many of     our <font color="blue">competitors</font> have experience <font color="blue"><font color="blue">significant</font>ly</font> greater than we have in the     <font color="blue">development</font> and testing of new or <font color="blue">improved products</font></td>
    </tr>
    <tr>
      <td>OUR PRODUCTS MAY BECOME OBSOLETE DUE TO TECHNOLOGICAL ADVANCES       We are developing products in areas that are <font color="blue">undergoing rapid technological</font>     advances  and we may be unable to take advantage of these advances</td>
    </tr>
    <tr>
      <td>In     addition, the <font color="blue">successful <font color="blue">application</font></font> of these <font color="blue">technological advances by</font>     <font color="blue">competitors</font> may render our <font color="blue">products obsolete</font></td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>is not aware of any studies that compare the <font color="blue">relative advantages</font>     or <font color="blue">disadvantages</font> of the Companyapstas chromium-based products as against these     other products</td>
    </tr>
    <tr>
      <td>Research supporting <font color="blue">competitors</font> &amp;apos  claims in the nutrition     <font color="blue">supplement market</font> is not subject to <font color="blue">mandatory review by</font> any <font color="blue">government</font>     agency</td>
    </tr>
    <tr>
      <td>Therefore, <font color="blue">new products</font> can appear and be brought to <font color="blue">market rapidly</font>     and  with little advance notice</td>
    </tr>
    <tr>
      <td><font color="blue">Competitive </font><font color="blue">products may</font> appear or be     <font color="blue">supported by new research</font> before we are able to respond <font color="blue">with new product</font>     <font color="blue">development</font> or <font color="blue">countervailing research</font></td>
    </tr>
    <tr>
      <td>If <font color="blue">competing products</font> are developed     that customers believe are superior to our products, sales of our products     <font color="blue">could decline</font> and our business would be harmed</td>
    </tr>
    <tr>
      <td>25       _________________________________________________________________         IF  WE  ARE NOT ABLE TO MEET REGULATORY REQUIREMENTS THAT APPLY TO OUR     PRODUCTS, WE WILL NOT BE ABLE TO MARKET THEM WITH CLAIMS FOR THEIR USE       The US Food and Drug Administration regulates the labeling and marketing     of our <font color="blue">dietary supplements</font> under the Dietary Supplement and Health Education     Act, <font color="blue">also known as</font> DSHEA Under DSHEA, we are required to submit for FDA     approval claims regarding the effect of our <font color="blue">dietary supplements</font> on the     structure or function of the body</td>
    </tr>
    <tr>
      <td>DSHEA also requires FDA approval for     health claims that relate <font color="blue">dietary supplements</font> to <font color="blue">disease prevention</font></td>
    </tr>
    <tr>
      <td>Under DSHEA, within 30 days after <font color="blue">first marketing</font> a product, a company must     submit to the FDA for review each claim (other than a <font color="blue">qualified health</font>     claim)  by  the  company that the product benefits <font color="blue">bodily structure</font> or     function</td>
    </tr>
    <tr>
      <td><font color="blue">If the FDA </font>believes that a claim suggests the product is intended     to diagnose, treat, cure or prevent a disease, it will reject the claim,     <font color="blue">usually within three months</font>, in which case the <font color="blue">company may no longer</font> make     the claim</td>
    </tr>
    <tr>
      <td>To date, the FDA has not rejected any of our claims for benefit     to <font color="blue">bodily structure</font> and function that are <font color="blue">significant</font> for the marketing of     our products</td>
    </tr>
    <tr>
      <td><font color="blue">Should the FDA </font>in the future reject <font color="blue">significant</font> claims, we may     be unable to <font color="blue">interest consumers</font> in purchasing our products</td>
    </tr>
    <tr>
      <td>The FDA review of health claims requires <font color="blue">significant</font> scientific <font color="blue">agreement</font>     that the totality of the <font color="blue">data supports</font> the claims that a <font color="blue">product prevents</font>     disease</td>
    </tr>
    <tr>
      <td>We applied for a <font color="blue">qualified health</font> claim on <font color="blue">December </font>19, 2003,     related to the prevention of diabetes</td>
    </tr>
    <tr>
      <td>In August 2005, the FDA recognized     <font color="blue"><font color="blue">chromium picolinate</font> as</font> a <font color="blue">safe nutritional supplement</font> that <font color="blue">may reduce risk</font> of     <font color="blue">insulin resistance</font> and possibly type 2 diabetes, and concluded that there is     <font color="blue">credible evidence</font> to support the following <font color="blue">qualified health</font> claim:       “One small study suggests that <font color="blue"><font color="blue">chromium picolinate</font> may reduce</font> the risk of     <font color="blue">insulin resistance</font>, and <font color="blue">therefore possibly may reduce</font> the risk of type 2     diabetes</td>
    </tr>
    <tr>
      <td>FDA concludes, however, that the existence of such a <font color="blue">relationship</font>     <font color="blue">between <font color="blue">chromium picolinate</font></font> and either <font color="blue">insulin resistance</font> or type 2 diabetes     is <font color="blue">highly uncertain</font></td>
    </tr>
    <tr>
      <td>”       The FDA declined to permit other <font color="blue">qualified health</font> claims that were proposed     by the Company</td>
    </tr>
    <tr>
      <td>WE ARE SUBJECT TO A FEDERAL TRADE COMMISSION CONSENT AGREEMENT THAT MAY     ADVERSELY AFFECT OUR BUSINESS       The Federal Trade Commission ( &amp;quote FTC &amp;quote ) regulates product-<font color="blue">advertising</font> claims,     and requires that claims be <font color="blue">supported by competent</font> and <font color="blue">reliable scientific</font>     evidence</td>
    </tr>
    <tr>
      <td>Prior to our <font color="blue">acquisition</font> of a California limited <font color="blue">partnership</font>     called <font color="blue">Nutrition </font>21 ( &amp;quote <font color="blue">Nutrition </font>21 LP &amp;quote ), the FTC opened an <font color="blue">inquiry into</font>     certain  of  the  claims  that <font color="blue">Nutrition </font>21 LP was making for chromium     picolinate</td>
    </tr>
    <tr>
      <td>The inquiry was <font color="blue">terminated by</font> the FTC with <font color="blue">Nutrition </font>21 LP     <font color="blue">entering into</font> a <font color="blue">consent <font color="blue">agreement</font></font> that requires <font color="blue">Nutrition </font>21 LP to support     its claims by competent and <font color="blue">reliable scientific</font> evidence</td>
    </tr>
    <tr>
      <td>After we acquired     <font color="blue">Nutrition </font>21 LP, we undertook <font color="blue">new clinical studies</font> to support the claims we     intended to make for our products</td>
    </tr>
    <tr>
      <td>The FTC has <font color="blue">subsequently audited</font> our     <font color="blue"><font color="blue">chromium picolinate</font> <font color="blue">advertising</font></font> and has not <font color="blue">found either</font> a lack of competent     and <font color="blue">reliable scientific</font> evidence or a failure to <font color="blue">comply with</font> the consent     <font color="blue">agreement</font></td>
    </tr>
    <tr>
      <td>We  are <font color="blue">discussing with</font> the FTC whether we should have any     <font color="blue">liability</font> for <font color="blue">weight loss <font color="blue">advertising</font></font> claims that were made on QVC, Inc</td>
    </tr>
    <tr>
      <td>televised  <font color="blue">shopping programs</font> for <font color="blue">Lite Bites </font><font color="blue">consumer products</font></td>
    </tr>
    <tr>
      <td><font color="blue">The FTC     </font>continues to monitor our <font color="blue">advertising</font> and could limit our <font color="blue">advertising</font> in ways     that could make marketing our products more <font color="blue">difficult</font> or result in lost     sales</td>
    </tr>
    <tr>
      <td><font color="blue">WE HAVE NO PROPRIETARY RIGHTS IN OUR OMEGA </font>3 PRODUCT       Although  the  <font color="blue"><font color="blue">manufacture</font>r</font>  of  our  omega-3  product uses a patented     <font color="blue">distillation</font> process to <font color="blue">remove toxins</font> and dioxins form the fish oils from     which the product is derived, the product itself is not patented</td>
    </tr>
    <tr>
      <td>Further it     competes with omega 3-<font color="blue">fatty acids</font> that are derived by <font color="blue">competitors</font> directly     from algae in a process that does not need to <font color="blue">remove toxins</font> and dioxin</td>
    </tr>
    <tr>
      <td>26       _________________________________________________________________             IF WE DO NOT ENFORCE OUR PATENT RIGHTS, OR ARE UNSUCCESSFUL ENFORCING OUR     PATENT RIGHTS, WE WILL FACE INCREASED COMPETITION       Our <font color="blue">significant</font> patents consist of:       ·     <font color="blue">three method</font> of use patents that expire in 2009 that cover the use of     <font color="blue">chromium picolinate</font> for improving body <font color="blue">composition</font>, glucose stabilization     and <font color="blue">cholesterol maintenance</font>,       ·     another method of use patent that expires in 2015 and covers the use of high     doses of <font color="blue">chromium picolinate</font> for glucose stabilization,       ·     <font color="blue">four patents</font> that expire in 2017 and cover the use of chromium for relieving     the symptoms of <font color="blue">depression</font> and pre-menstrual syndrome,       ·     two <font color="blue">composition</font> of matter patents that expire in 2017 and <font color="blue">cover chromium</font>     picolinate and biotin <font color="blue">composition</font>s and their use for <font color="blue">stabilizing serum</font>     glucose,       ·     one <font color="blue">composition</font> of matter patent that expires in 2017 and covers a     <font color="blue">composition</font> of <font color="blue">chromium picolinate</font> and other <font color="blue">ingredients</font> and its use for     improving body <font color="blue">composition</font>, and       ·     11 other chromium-based patents that expire in 2017, 2018 and 2021 that     cover a range of <font color="blue">composition</font>s and uses for which we do not <font color="blue">offer products</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">also applied</font> for eight other <font color="blue">United States </font>patents relating to     improving insulin sensitivity, reducing hyperglycemia, and treatment of     diabetes, dyslipidemia, hypercholesterolemia and other diseases</td>
    </tr>
    <tr>
      <td>If we do     not obtain <font color="blue">patent protection</font>, our ability to develop and <font color="blue">market products</font> for     these disease states will be adversely affected, since we will be subject to     <font color="blue">competition on</font> the products we develop</td>
    </tr>
    <tr>
      <td>To date, we have not <font color="blue">been denied</font> a     <font color="blue">patent on</font> any <font color="blue">application</font></td>
    </tr>
    <tr>
      <td>However, there is no guarantee a <font color="blue">patent will</font> be     granted in <font color="blue">each instance</font></td>
    </tr>
    <tr>
      <td><font color="blue">Composition </font>of matter patents protect the <font color="blue">manufacture</font>, sale or use of a     product</td>
    </tr>
    <tr>
      <td>Method of use     patents are more <font color="blue">difficult</font> to enforce since the actual infringer is the     person that takes the <font color="blue">chromium picolinate</font> for the <font color="blue">patented use</font></td>
    </tr>
    <tr>
      <td>In order to     enforce a method of use patent against <font color="blue"><font color="blue">manufacture</font>r</font>s or sellers, the patent     owner  must  <font color="blue">prove contributory</font> or induced infringement, which is more     <font color="blue">difficult</font> than enforcing a <font color="blue">composition</font> of matter patent</td>
    </tr>
    <tr>
      <td>We are from time to time <font color="blue">faced with competition from companies</font>, including     importers, that disregard our <font color="blue">patent rights</font></td>
    </tr>
    <tr>
      <td><font color="blue">Companies </font><font color="blue">frequently</font> take     <font color="blue">calculated risks</font> that we will not sue to enforce our <font color="blue">patent rights</font> against     them  and  that  we will not prevail in any suits that we do bring</td>
    </tr>
    <tr>
      <td>In     considering whether to bring a suit, we take <font color="blue">into account</font> the <font color="blue">legal costs</font> of     enforcing the patent</td>
    </tr>
    <tr>
      <td><font color="blue">Competitors </font>who disregard our <font color="blue">patent rights</font> can undercut our prices because     they avoid paying for the <font color="blue">technology</font> in their products</td>
    </tr>
    <tr>
      <td>We brought <font color="blue">approximately</font> 20 <font color="blue">patent infringement suits</font> under a <font color="blue">composition</font> of     matter patent that expired in 2001</td>
    </tr>
    <tr>
      <td>These suits were settled in our favor,     in some cases by <font color="blue">agreement</font> of the <font color="blue">infringing party</font> to <font color="blue">purchase designated</font>     amounts of <font color="blue">products from us</font>, and in other <font color="blue">cases by cash payments</font> to us</td>
    </tr>
    <tr>
      <td>We     <font color="blue">also brought one infringement suit under</font> our patent that covers the use of     <font color="blue">chromium picolinate</font> for <font color="blue">stabilizing serum</font> glucose</td>
    </tr>
    <tr>
      <td>This suit was <font color="blue">settled by</font>     <font color="blue">agreement</font>  of  the  infringing  party  to  <font color="blue">purchase from us</font> all of its     <font color="blue"><font color="blue">requirement</font>s</font> for <font color="blue">chromium picolinate</font> over a <font color="blue">designated period</font></td>
    </tr>
    <tr>
      <td>We currently     have <font color="blue">one patent infringement suit pending</font>, and are <font color="blue">evaluating bring</font> other     <font color="blue">patent infringement suits</font></td>
    </tr>
    <tr>
      <td>27       _________________________________________________________________         IF  WE  ARE UNABLE TO MAINTAIN A NASDAQ LISTING FOR OUR SECURITIES THE     LIQUIDITY OF OUR STOCK WILL BE REDUCED AND INVESTORS MAY BE UNABLE TO SELL     THEM, OR MAY BE ABLE TO SELL THEM ONLY AT REDUCED PRICES       We  are  currently in <font color="blue">compliance with</font> Nasdaqapstas minimum dlra1dtta00 bid price     <font color="blue">requirement</font> for <font color="blue"><font color="blue">continued listing</font> on</font> the <font color="blue">Nasdaq Capital Market</font></td>
    </tr>
    <tr>
      <td>If we fail     to meet the dlra1dtta00 bid price <font color="blue">requirement</font> for at least 30 <font color="blue">consecutive</font> business     days, we will be provided time to achieve compliance, generally up to one     <font color="blue">year provided</font> we satisfy the criteria for <font color="blue">continued listing</font> other than the     <font color="blue">minimum bid price</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">period during which</font> our <font color="blue"><font color="blue"><font color="blue">common stock</font> will</font> continue</font> to     be listed on the <font color="blue">Nasdaq Capital Market</font> may be <font color="blue">extended further</font> subject to     <font color="blue">certain conditions</font></td>
    </tr>
    <tr>
      <td><font color="blue">Throughout </font>this period the Company can <font color="blue">regain compliance</font>     by maintaining a dlra1dtta00 per share bid price for a minimum of 10 <font color="blue">consecutive</font>     business days</td>
    </tr>
    <tr>
      <td><font color="blue">Should the Company </font>not be in <font color="blue">compliance at</font> the end of this     period,  its <font color="blue"><font color="blue">common stock</font> will</font> be subject to <font color="blue">delisting from</font> the Nasdaq     Capital Market</td>
    </tr>
    <tr>
      <td>Under <font color="blue">certain circumstances</font>, to ensure that the company can     sustain long-term compliance, Nasdaq may require the closing bid price to     equal or to exceed the dlra1dtta00 <font color="blue">minimum bid price</font> <font color="blue">requirement</font> for more than 10     <font color="blue">consecutive</font> business days before determining that a <font color="blue">company complies with</font>     Nasdaqapstas minimum dlra1dtta00 bid price <font color="blue">requirement</font></td>
    </tr>
    <tr>
      <td>The liquidity of our <font color="blue"><font color="blue">common stock</font> will</font> be reduced if our <font color="blue">securities fail</font> to     maintain a Nasdaq listing</td>
    </tr>
    <tr>
      <td><font color="blue">Purchasers </font>of our <font color="blue">common stock</font> <font color="blue">would likely</font> find     it more <font color="blue">difficult</font> to sell our <font color="blue">common stock</font>, and the <font color="blue">market value</font> of our     <font color="blue">common stock</font> <font color="blue">would likely</font> decline</td>
    </tr>
    <tr>
      <td>In addition, if we fail to maintain a Nasdaq listing for our securities, and     no other <font color="blue">exclusion from</font> the <font color="blue">definition</font> of a  &amp;quote penny stock &amp;quote  under the Exchange     Act  is  available,  then  any broker engaging in a <font color="blue">transaction</font> in our     <font color="blue">securities would</font> be required to provide any <font color="blue">customer with</font> a <font color="blue">risk <font color="blue">disclosure</font></font>     document,  <font color="blue">disclosure</font>  of <font color="blue">market quotations</font>, if any, <font color="blue">disclosure</font> of the     <font color="blue">compensation</font> of the broker-dealer and its <font color="blue">salesperson</font> in the <font color="blue">transaction</font>,     and <font color="blue">monthly account statements showing</font> the <font color="blue">market value</font>s of our securities     held  in  the  customerapstas  <font color="blue">accounts</font></td>
    </tr>
    <tr>
      <td>The  bid and <font color="blue">offer quotation</font> and     <font color="blue">compensation</font> information must be <font color="blue">provided prior</font> to <font color="blue">effecting</font> the <font color="blue">transaction</font>     and must be <font color="blue">contained on</font> the customerapstas confirmation</td>
    </tr>
    <tr>
      <td>If <font color="blue">brokers become</font>     subject to the  &amp;quote penny stock &amp;quote  rules when engaging in <font color="blue">transaction</font>s in our     securities, they <font color="blue">would become less willing</font> to engage in these <font color="blue">transaction</font>s,     <font color="blue">which will</font> make it more <font color="blue">difficult</font> for purchasers of our <font color="blue">common stock</font> to     dispose of their shares</td>
    </tr>
    <tr>
      <td>Should  we  fail  to maintain our Nasdaq listing and should we then or     thereafter not be listed on the <font color="blue">Bulletin Board </font>we will be required to redeem     our <font color="blue">Preferred Stock </font>before the four-year period fixed for maturity</td>
    </tr>
  </tbody>
</table>